liver cancer and colorectal cancer
Conditions
Interventions
control group:None
experimental group:In patients with liver cancer, 0.5% ropivacaine T8 ESPB was 15ml on each side (25 cases).Colorectal cancer patients 0.5% ropivacaine T12 ESPB 15ml on each side (25 cases)
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. ASA I-III; 2. Patients with hepatectomy and radical resection of colorectal cancer; 3. be able to cooperate and correctly understand Chinese and express well; 4. Agree to the experimental program and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Chronic opioid users; 2. Local anesthetics, opioids and other allergic patients; 3. Patients with local skin infection and bleeding at the puncture site of anesthesia; 4. Patients with coagulation dysfunction and abnormal platelet function; 5. The anesthesiologist or surgeon considers the patient inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of sleep disturbances due to pain on the night of surgery and the following night;The use of remedial analgesics within 72h after surgery;Number of postoperative analgesic pump compressions;Complications such as nauseas and vomiting;Duration of operation and dosage of analgesics during operation; | — |
Countries
China
Contacts
Public ContactYang Jing
West China Hospital, Sichuan University
Outcome results
None listed